Recombinant cell lines that functionally express human ion channels are a valuable tool to screen for drugs targeting pain, stroke, or metabolic diseases but also to test candidates for negative side effects that induce proarrhythmia (CIPA panel). A set of six sodium and potassium channel cell lines developed by B’SYS (CH) and a calcium channel cell line from NMI TT (GER) and Steinbeis Innovation (GER) are distributed by acCELLerate in assay ready format. The very stably and successfully performing CHO-hCaV1.2 cells have been engineered by using Steinbeis’ proprietary expression technology IGAMI®.
Patch Ready Cells can be used instantly after thawing and have been qualified on a SyncroPatch 384PE (Nanion, GER), a Q-Patch, and a Qube 384 (Sophion Bioscience, SWE) to demonstrate their applicability in high-throughput cardiotoxicity testing. Patch Ready Cells are provided in single-use aliquots of cryopreserved cells together with suitable amounts of recovery and patch buffer.